Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrique Ocio

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Haematologica|April 26, 2015
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trialMaría-Victoria Mateos, Albert Oriol, Laura Rosiñol, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
The Lancet. Oncology|June 5, 2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengass, Saad Usmani, S Vincent Rajkumar, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Haematologica|April 26, 2015
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trialMaría-Victoria Mateos, Albert Oriol, Laura Rosiñol, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
The Lancet. Oncology|June 5, 2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengass, Saad Usmani, S Vincent Rajkumar, et al.
Pageof 2